A Tale of Two Sexes: Rapamycin and Friends Protect Bone in Females, Lifespan in Males

RapAdmin · June 21, 2026, 4:31am

Three of the best-validated lifespan-extending drugs — rapamycin, acarbose, and 17α-estradiol — all preserved spongy (trabecular) bone in aging female mice but did almost nothing in males.

Osteoporosis drugs strengthen bone, but they do nothing about the muscle weakness, poor balance, and failing eyesight that actually cause most of the falls that break bones. That is the appeal of “geroprotectors” — drugs that slow aging itself and might fix several of these problems at once. The catch is that almost nobody has carefully checked what these drugs do to the skeleton over the long haul.

A team at the University of Sheffield, using mouse cohorts from the US National Institute on Aging’s Interventions Testing Program, did exactly that. They took genetically diverse UM-HET3 mice, treated them for most of their adult lives with rapamycin (an mTOR inhibitor), acarbose (a carb-blocker that flattens blood-sugar spikes), or 17α-estradiol (a “non-feminizing” estrogen), and then imaged their leg bones with micro-CT at 12 and 22 months — roughly mouse middle and old age.

The headline result is a clean dissociation. In females, all three drugs measurably preserved trabecular bone — the lattice-like inner scaffold inside the bone — at 22 months, with rapamycin and 17α-estradiol producing the biggest effects. In males, the effects were essentially nil. That sex split is the surprise, because the lifespan literature points the other way: acarbose and 17α-estradiol extend lifespan mainly or only in male mice.

There is an important nuance under the hood. The drugs did not appear to build new bone. They preserved the number of trabecular struts rather than thickening them, and they did almost nothing to the dense outer cortical shell that carries most mechanical load. That pattern looks like holding the line — slowing the loss of existing architecture, probably by damping inflammation and bone-resorbing osteoclasts — rather than the muscular anabolic rebuild you get from approved drugs like teriparatide.

The practical takeaway is cautious but real: drugs being pursued for healthy longevity may carry a skeletal bonus, at least in females, on top of their other benefits. But the sex-specificity is a warning. You cannot assume a longevity drug helps every tissue, in every sex, the same way. The mechanisms diverge, and the dose, timing, and biological sex all matter.

Actionable Insights

For a longevity-minded reader, the magnitudes matter more than the headline. In aged (22-month) female mice, relative to same-age controls, the paper reports trabecular bone density increases of roughly +47% with 17α-estradiol, +34% with rapamycin, and +15% with acarbose. In standardized terms these are large statistical effects (posterior probability of a “large” effect size: 92.7% for 17α-estradiol, 85.6% for rapamycin), but note the absolute gains are small (≈1.1–1.5 percentage points of bone volume fraction on a low ~3% baseline). The big-looking percentages come from a low denominator, not a dramatic bone rebuild.

Honest take-home messages:

This is mouse data, female-specific, and not lifespan-tested here.
Mechanism is preservation, not construction. These drugs slowed loss of trabecular struts; they did not thicken cortical bone (the part that resists fracture most). Do not expect teriparatide-like rebuilding.
Timing matters. Most bone loss happened before 12 months. Late-starting interventions had less to work with — a “start early to preserve” signal.
The genuinely useful longevity move remains the boring one the paper implicitly endorses: protect bone and the muscle/balance/vision systems that prevent falls.

Source:

Open Access Paper: Geroprotective interventions preserve trabecular bone during ageing in female mice
Institutions: University of Sheffield (Division of Clinical Medicine; Insigneo Institute; Healthy Lifespan Institute), UK; with the University of Michigan (Department of Pathology & Geriatrics Center), USA.
Country: United Kingdom (lead) / USA (cohorts and ITP).
Venue: bioRxiv — a preprint server, not a peer-reviewed journal.
Impact Evaluation: This is a bioRxiv preprint that has not been certified by peer review, so it has no Journal Impact Factor.

Pulsed Dosing Rapamycin Studies

To bypass these off-target sequelae, researchers have investigated alternative dosing regimens. These methods exploit the differential disassembly and recovery kinetics of mTORC1 versus mTORC2, demonstrating that pulsed, intermittent, or transient schedules can preserve or recapitulate lifespan extension while minimizing metabolic dysfunction.

Below is a systematic breakdown of the primary animal research papers evaluating non-continuous rapamycin regimens.

Comparative Matrix of Intermittent Rapamycin Regimens

Study	Animal Model	Dosing Regimen & Delivery Route	Key Longevity & Physiological Outcomes
Anisimov et al. (2011)	Female 129/Sv mice (2 months old)	1.5 mg/kg subcutaneously; 3x per week for 2 weeks per month (alternating 2 weeks on / 2 weeks off)	Significant lifespan extension (22.9% survived past maximum control lifespan); delayed spontaneous tumorigenesis; reduced age-related weight gain.
Leontieva et al. (2014)	Obese male mice on high-fat diet (9 months old)	1.5 mg/kg i.p. once per week	Robustly extended survival (100% alive at 2 years vs. 40% in controls); transiently reduced weight gain; improved aging biomarkers.
Arriola Apelo et al. (2016)	Female C57BL/6J mice (20 months old)	2 mg/kg i.p. once every 5 days	Extended median and maximal lifespan in late life; completely avoided glucose intolerance and immune suppression observed in daily cohorts.
Bitto et al. (2016)	Male & Female C57BL/6J mice (20 months old)	8 mg/kg/day i.p. or 126 ppm dietary eRapa for only 3 months (90 days), then completely discontinued	Increased remaining life expectancy by up to 60% post-treatment; improved grip strength; induced long-lasting gut microbiome remodeling.
Baghdadi et al. (2024)	Male & Female C3B6F1 hybrid mice (6 or 10 months old)	42 mg/kg encapsulated dietary rapamycin on an alternating weekly feeding schedule (1 week on / 1 week off)	Lifespan extension equaled continuous feeding in males; partially rescued glucose intolerance; slightly less effective for female survival.

Granular Analysis of Individual Studies

1. Alternate-Week Maintenance via Diet

Study: Baghdadi et al. (2024)
Dosing Period and Regimen: Mice were given microencapsulated rapamycin at a high dose of 42 mg/kg of diet, alternating every week (1 week on rapamycin food, followed by 1 week on standard control food). Treatment was initiated at either 6 or 10 months of age and maintained throughout their remaining lifespan.
Core Findings: In male mice, this 1-week-on/1-week-off protocol extended lifespan to the exact same degree as continuous feeding, while significantly preserving glucose tolerance. However, a distinct sexual dimorphism was noted: intermittently fed female mice experienced slightly shorter lifespan extension relative to their continuously fed counterparts.

2. Late-Life Dosing Every 5 Days

Study: Arriola Apelo et al. (2016)
Dosing Period and Regimen: Aged female mice (20 months old, equivalent to roughly 60–65 human years) received intraperitoneal (i.p.) injections of 2 mg/kg rapamycin exactly once every 5 days.
Core Findings: This regimen significantly extended both mean and maximum lifespan, even when initiated in late life. Crucially, the 5-day interval allowed sufficient clearance to prevent the suppression of mTORC2, meaning treated mice showed no signs of impaired glucose or insulin tolerance, nor changes in overall body composition compared to controls. This built upon their previous pilot work demonstrating that a 5-day or 7-day interval maintains a therapeutic window favoring mTORC1 specificity over mTORC2 disruption (Arriola Apelo et al., 2015).

3. Rigid Weekly Administration in Obese Models

Study: Leontieva et al. (2014)
Dosing Period and Regimen: 9-month-old male mice on a high-fat diet were put on a strict weekly schedule: 1.5 mg/kg via i.p. injection once per week for a duration of 11 months. Alternate groups were evaluated at 1.5 mg/kg or 0.5 mg/kg injected 3 times per week every other week.
Core Findings: While continuous rapamycin can exacerbate certain diabetic phenotypes in obese models, this once-weekly injection regimen significantly enhanced survival. At the 2-year mark, 100% of the once-weekly rapamycin cohort was alive compared to only 40% of the untreated high-fat diet control group. It also led to a transient, controlled reduction in weight gain.

4. Bimonthly Pulsed Injections

Study: Anisimov et al. (2011)
Dosing Period and Regimen: Starting at a young age (2 months old), inbred female mice were treated with 1.5 mg/kg rapamycin via subcutaneous injections. The dosing schedule was explicitly pulsed: administered 3 times per week for 2 consecutive weeks, followed by 2 weeks of total drug omission, repeated cyclically throughout their entire lifespan.
Core Findings: This represented the first definitive proof that a long-term, non-continuous schedule could slow the rate of aging and prolong lifespan in normal inbred mice. The pulsed strategy effectively curbed age-related weight gain, lowered the development of spontaneous tumors, and increased the survival rate of the oldest individuals (maximum lifespan) by 22.9%.

5. Macro-Transient “Drug Holiday” Model

Study: Bitto et al. (2016)
Dosing Period and Regimen: Rather than micro-pulsing every few days, this study evaluated a single, heavy transient window. Middle-aged mice (20 months old) were given either 8 mg/kg/day via i.p. injection or 126 ppm microencapsulated dietary rapamycin for exactly 3 months (90 days). After day 90, the drug was permanently withdrawn for the remainder of their lives.
Core Findings: A mere 90 days of late-life treatment was sufficient to boost remaining life expectancy post-treatment by up to 60%, yielding a 14% to 16% increase in overall lifespan from birth in males. The health benefits (such as enhanced motor coordination and cardiac configurations) persisted long after the drug cleared the system, accompanied by permanent, favorable shifts in the gut microbiome.

Scholarly Debates & Knowledge Gaps

The Sexual Dimorphism Anomaly: There is an ongoing debate regarding why female mice generally derive greater longevity benefits from continuous rapamycin than males, yet appear less responsive to certain intermittent schedules (e.g., the alternating weekly feed in Baghdadi et al., 2024). Pinpointing whether this stems from sex-specific pharmacokinetics, differences in fat mass distribution, or varied baseline mTORC2 sensitivity remains an open field of study.
Optimal Trough Levels vs. Peak Levels: It is unresolved whether the success of pulsed dosing relies entirely on reaching a near-zero “trough” concentration to allow tissue-specific mTORC2 recovery, or if the brief, high-concentration “peak” is what drives autophagy and clears senescent cells to deliver long-term healthspan extension.
Translational Extrapolation: Animal models possess a substantially faster metabolic rate and shorter rapamycin half-life (roughly 15 hours in mice) than humans (60–90 hours). Additional pharmacokinetic data mapping mammalian target inhibition in large animal models is required to establish whether a weekly human equivalent dose accurately replicates the molecular “oscillations” validated in these rodent designs.

References

Anisimov, V. N., Zabezhinski, M. A., Popovich, I. G., et al. (2011). Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle, 10(24), 4230-4236. https://doi.org/10.4161/cc.10.24.18486
Cited by: 423

Arriola Apelo, S. I., Neuman, Joshua C., Baar, Emma L., et al. (2015). Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell, 15(1), 28-38. https://doi.org/10.1111/acel.12405
Cited by: 214

Arriola Apelo, S. I., Pumper, C. P., Baar, E. L., et al. (2016). Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 71(7), 876-881. https://doi.org/10.1093/gerona/glw064
Cited by: 168

Baghdadi, M., Nespital, T., Monzó, C., et al. (2024). Intermittent rapamycin feeding recapitulates some effects of continuous treatment while maintaining lifespan extension. Molecular Metabolism, 81, 101902. https://doi.org/10.1016/j.molmet.2024.101902
Cited by: 30

Bitto, A., Ito, T. K, Pineda, V. V, et al. (2016). Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. eLife, 5. https://doi.org/10.7554/elife.16351
Cited by: 544

Leontieva, O. V., Paszkiewicz, G. M., & Blagosklonny, M. V. (2014). Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high‐fat diet. Aging Cell, 13(4), 616-622. https://doi.org/10.1111/acel.12211
Cited by: 99

Rapamycin Longevity News